{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:03:00Z","timestamp":1761948180886},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","funder":[{"name":"National Counsel of Technological and Scientific Development, CNPq","award":["564778\/2010-9"],"award-info":[{"award-number":["564778\/2010-9"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40744-016-0036-0","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T10:18:56Z","timestamp":1468232336000},"page":"353-361","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil"],"prefix":"10.1007","volume":"3","author":[{"given":"Marina Amaral de \u00c1vila","family":"Machado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Ferre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano Soares de","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra Maciel","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli Iola Gurgel","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00e2ngela Leal","family":"Cherchiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"issue":"9570","key":"36_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet"},{"key":"36_CR2","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"issue":"5","key":"36_CR3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/ard.61.5.429","volume":"61","author":"A Boonen","year":"2002","unstructured":"Boonen A, van der Heijde D, Landew\u00e9 R, Spoorenberg A, Schouten H, Rutten-van M\u00f6lken M, Guillemin F, Dougados M, Mielants H, de Vlam K, van der van der Tempel H, Linden S. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002;61(5):429\u201337.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"36_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.rbr.2015.06.002","volume":"56","author":"VF Azevedo","year":"2016","unstructured":"Azevedo VF, Rossetto CN, Lorencetti PG, Tramontin MY, Fornazari B, Ara\u00fajo DV. Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system. Rev Bras Reumatol. 2016;56(2):131\u20137. doi: 10.1016\/j.rbr.2015.06.002 .","journal-title":"Rev Bras Reumatol."},{"issue":"6","key":"36_CR5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"36_CR6","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Portaria n\u00ba 640, de 24 de julho de 2014. Aprova o Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Espondilite Ancilosante. 2014. Available at: http:\/\/portalsaude.saude.gov.br\/images\/pdf\/2014\/julho\/25\/pcdt-espondilite-ancilosante-2014.pdf . Accessed 22 Dec 2014."},{"key":"36_CR7","unstructured":"Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, Turchetti G. A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol. 2012;30(4) Suppl 73:S136\u2013S141."},{"issue":"9779","key":"36_CR8","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/S0140-6736(11)60054-8","volume":"377","author":"J Paim","year":"2011","unstructured":"Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The Brazilian health system: history, advances, and challenges. Lancet. 2011;377(9779):1778\u201397.","journal-title":"Lancet."},{"issue":"3","key":"36_CR9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12325-012-0007-y","volume":"29","author":"MM Bonafede","year":"2012","unstructured":"Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3):234\u201348.","journal-title":"Adv Ther."},{"issue":"5","key":"36_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s11096-015-0124-1","volume":"37","author":"V Escudero-Vilaplana","year":"2015","unstructured":"Escudero-Vilaplana V, Ram\u00edrez-Herr\u00e1iz E, Ala\u00f1\u00f3n-Plaza E, Trovato-L\u00f3pez N, Garc\u00eda-Vicu\u00f1a R, Carre\u00f1o-P\u00e9rez L, Morell-Baladr\u00f3n A, Sanjurjo-S\u00e1ez M. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. Int J Clin Pharm. 2015;37(5):808\u201314. doi: 10.1007\/s11096-015-0124-1 .","journal-title":"Int J Clin Pharm."},{"issue":"12","key":"36_CR11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.5414\/CP201707","volume":"50","author":"V Nell-Duxneuner","year":"2012","unstructured":"Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis. Int J Clin Pharmacol Ther. 2012;50(12):867\u201372.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"36_CR12","unstructured":"National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 143. Adalimumab, etanercept and infliximab for ankylosing spondylitis. Review date October 2010. Available at: https:\/\/www.nice.org.uk\/guidance\/ta143 . Accessed 15 Jan 2016."},{"issue":"11","key":"36_CR13","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3899\/jrheum.100099","volume":"37","author":"B Str\u00f6mbeck","year":"2010","unstructured":"Str\u00f6mbeck B, Englund M, Bremander A, Jacobsson LT, Kedza L, Kobelt G, Petersson IF. Cost of illness from the public payers\u2019 perspective in patients with ankylosing spondylitis in rheumatological care. J Rheumatol. 2010;37(11):2348\u201355. doi: 10.3899\/jrheum.100099 .","journal-title":"J Rheumatol"},{"key":"36_CR14","doi-asserted-by":"publisher","unstructured":"Oliveira Junior HA, dos Santos JB, Acurcio FA, Almeida AM, Kakehasi AM, Alvares, de Carvalho LFD, Cherchiglia ML. Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (Sistema unico de Saude), Minas Gerais, Brazil. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):403\u201312. doi: 10.1586\/14737167.2015.1003367 .","DOI":"10.1586\/14737167.2015.1003367"},{"issue":"11","key":"36_CR15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","volume":"30","author":"AR Giardina","year":"2010","unstructured":"Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, Triolo G. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30(11):1437\u201340.","journal-title":"Rheumatol Int"},{"key":"36_CR16","doi-asserted-by":"crossref","unstructured":"Machado MA, Barbosa MM, Almeida AM, de Ara\u00fajo VE, Kakehasi AM, Andrade EI, Cherchiglia ML, Acurcio Fde A. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33(9):2199-213.","DOI":"10.1007\/s00296-013-2772-6"},{"issue":"1","key":"36_CR17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40261-014-0246-6","volume":"35","author":"A Migliore","year":"2015","unstructured":"Migliore A, Bizzi E, Bernardi M, Diamanti AP, Lagan\u00e0 B, Petrella L. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clin Drug Investig. 2015;35(1):23\u20139.","journal-title":"Clin Drug Investig."},{"issue":"10","key":"36_CR18","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/rheumatology\/ket249","volume":"52","author":"A Spadaro","year":"2013","unstructured":"Spadaro A, Lubrano E, Marchesoni A, D\u2019Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C. Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study. Rheumatology (Oxford). 2013;52(10):1914\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"36_CR19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/rheumatology\/ker169","volume":"51","author":"LE Kristensen","year":"2012","unstructured":"Kristensen LE, Petersson IF, Geborek P, J\u00f6ud A, Saxne T, Jacobsson LT, Englund M. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford). 2012;51(2):243\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"36_CR20","doi-asserted-by":"crossref","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13(3):R94.","DOI":"10.1186\/ar3369"},{"issue":"2","key":"36_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/S0102-30982009000200007","volume":"26","author":"FA Acurcio","year":"2009","unstructured":"Acurcio FA, Brand\u00e3o CM, Guerra AA Jr, Cherchiglia ML, Andrade EI, Almeida AM, da Silva GD, de Queiroz OV, Faleiros DR. Perfil demogr\u00e1fico e epidemiol\u00f3gico dos usu\u00e1rios de medicamentos de alto custo no Sistema \u00danico de Sa\u00fade. Rev bras estud popul. 2009;26(2):263\u201382.","journal-title":"Rev bras estud popul."},{"key":"36_CR22","doi-asserted-by":"crossref","unstructured":"Brand\u00e3o CM, Guerra AA Jr, Cherchiglia ML, Andrade EI, Almeida AM, da Silva GD, de Queiroz OV, Faleiros DR, Acurcio Fde A. Expenses of the Brazilian Ministry of Health for high-cost drugs: a demographic and clinical analysis. Value Health. 2011;14(5) Suppl 1:S71\u2013S77.","DOI":"10.1016\/j.jval.2011.05.028"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-016-0036-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:10:49Z","timestamp":1498327849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40744-016-0036-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s40744-016-0036-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}